KURA ONCOLOGY, INC. (NASDAQ:KURA) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On May 15, 2017, Kura Oncology, Inc. (the Company) issued a press
release announcing its financial results for the first quarter
ended March 31, 2017. A copy of this press release is furnished
herewith as Exhibit 99.1.
The information contained in this Current Report on Form 8-K
under Item 2.02 and Exhibit 99.1 hereto are being furnished and
shall not be deemed to be filed for the purposes of Section 18 of
the Securities and Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section and will not be
incorporated by reference into any registration statement filed
by the Company, under the Securities Act of 1933, as amended,
unless specifically identified as being incorporated therein by
reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press release dated May 15, 2017 |
About KURA ONCOLOGY, INC. (NASDAQ:KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. KURA ONCOLOGY, INC. (NASDAQ:KURA) Recent Trading Information
KURA ONCOLOGY, INC. (NASDAQ:KURA) closed its last trading session 00.00 at 9.00 with shares trading hands.
